F/TDF

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

HIV InfectionHepatitis BHIV-1 InfectionHIV

326 competitors in HIV Infection

#DrugCompanyPhaseTrials

1

Hivid

CConrado Roberto Hoffmann Filho

Phase 3

92

PEG-Intron

Merck & Co.

Phase 3

—3

Megace

Bristol-Myers Squibb

Phase 3

—4

Proleukin

IIovance Biotherapeutics, Inc.

Phase 3

25

Foscavir

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 3

16

TWINRIX™

GSK

Phase 3

17

F/TAF

Gilead

Phase 3

18

PTM SEMA

Gilead

Phase 3

19

Motexafin Gadolinium

PPharmacyclics LLC.

Phase 3

—10

Aspiverin

IInternational Partnership for Microbicides, Inc.

Phase 3

—Show 33 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Hepatitis B1 trial

Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults

Completed·Gilead·Phase 3·NCT03547908·244 enrolled

HIV-1 infection1 trial

Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection

Active, not recruiting·Gilead·Phase 3·NCT02842086·5,399 enrolled

HIV infection1 trial

Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection

Active, not recruiting·Gilead·Phase 3·NCT04994509·5,368 enrolled

HIV Infections1 trial

Pioneering Research to Optimize Pre-exposure Prophylaxis (PrEP) Expansion With Lenacapavir (LEN)

Recruiting·Gilead··NCT07473778·3,000 enrolled

HIV1 trial

PURPOSE-1: Lenacapavir PrEP for HIV Prevention

Completed·Gilead·Phase 3·NCT04925752·5,338 enrolled

Details

Drug Info

Related News